Buy Zoetis Stock Today?

10:10am, Friday, 31'st Oct 2025
Zoetis (ZTS) stock warrants your attention. Why? Because it offers high margins – indicative of pricing power and the ability to generate cash – at a discounted price.
Besides Wall Street's top-and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quart
ZTS is poised for another earnings beat as rising demand for companion animal products like Simparica Trio and Apoquel drives expected Q3 revenue growth.
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Portela becomes first mAb therapy with a three-month dosing interval approved for the alleviation of pain associated with OA in cats.
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms.
Zoetis (ZTS) concluded the recent trading session at $147.53, signifying a +1.09% move from its prior day's close.
Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their bu
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zoetis Stock: Outlook Remains Muted

06:48am, Tuesday, 21'st Oct 2025
Zoetis Inc. (NYSE:ZTS) is currently in its final 18th phase of the Adhishthana cycle on the weekly charts. Having formed a poor triad structure, the stock's outlook doesn't look encouraging.
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Lenivia approval by Health Canada marks major milestone in the company's continued innovation for canine OA pain.
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ZTS secures CVMP's positive opinion recommending the approval of Lenivia, a long-acting OA pain therapy for dogs, with the final decision expected in late 2025.
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--If approved, Lenivia will be a new antibody therapy that reduces OA pain in dogs for three months with one injection.

Zoetis Declares Fourth Quarter 2025 Dividend

04:15pm, Thursday, 09'th Oct 2025
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the fourth quarter of 2025. The dividend will
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE